Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone011-61-3-8412-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions
What is Genetic Technologies' stock symbol?
Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."
Has Genetic Technologies been receiving favorable news coverage?
News articles about GENE stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genetic Technologies earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Genetic Technologies.
Who are some of Genetic Technologies' key competitors?
Some companies that are related to Genetic Technologies include BIONDVAX PHARMA/S (BVXV), Genocea Biosciences (GNCA), Microbot Medical (MBOT), Allena Pharmaceuticals (ALNA), INmune Bio (INMB), Idera Pharmaceuticals (IDRA), Neon Therapeutics (NTGN), Curis (CRIS), Polarityte (PTE), Organovo (ONVO), Entera Bio (ENTX), BioCardia (BCDA), Outlook Therapeutics (OTLK), Vical (VICL) and aTyr Pharma (LIFE).
What other stocks do shareholders of Genetic Technologies own?
Who are Genetic Technologies' key executives?
Genetic Technologies' management team includes the folowing people:
- Dr. Paul Alexander Kasian Ph.D., Exec. Chairman & CEO (Age 62)
- Dr. Jerzy Muchnicki, Exec. Director & Bus. Devel. Director
- Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, COO, CFO & Company Sec.
Who are Genetic Technologies' major shareholders?
Genetic Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.95%).
Which institutional investors are buying Genetic Technologies stock?
GENE stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
How do I buy shares of Genetic Technologies?
Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genetic Technologies' stock price today?
One share of GENE stock can currently be purchased for approximately $2.82.
How big of a company is Genetic Technologies?
What is Genetic Technologies' official website?
How can I contact Genetic Technologies?
Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 011-61-3-8412-7000 or via email at [email protected]
MarketBeat Community Rating for Genetic Technologies (NASDAQ GENE)
MarketBeat's community ratings are surveys of what our community members think about Genetic Technologies and other stocks. Vote "Outperform" if you believe GENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
